Sartorius, Pall reap vaccine-gear bounty

Sartorius Stedim Biotech credits much of its 2009 financial success to sales of single-use products for vaccine production. "High demand was driven by vaccine manufacturers who required considerable quantities of single-use bags and filters used in the production of the vaccine against the H1N1 virus. This effect contributed around two percentage points to growth," the company reports to shareholders.

Order intake for the biotech division jumped 12 percent, thanks in large part to the disposables. The good news is balanced by bad: Its large-scale bioreactor systems business "slightly declined."

"Pharmaceutical manufacturers are increasingly switching from stationary installed stainless steel equipment to flexibly deployable single-use products made of plastic," the company says. It promises to launch "highly attractive new products" in 2010.

Pall Life Sciences, too, reports better than 10 percent biopharma sales growth for the quarter that ended in October 2009. "Sales within pharmaceutical submarkets increased 9.8 percent with strong consumables growth in all geographies. Vaccine production remains high," it told shareholders.

- see the Sartorius annual review
- here's the Pall report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.